Search

Your search keyword '"Lagarde, Sjoerd"' showing total 710 results
Start Over Author "Lagarde, Sjoerd"
710 results on '"Lagarde, Sjoerd"'

1. Effects of Neoadjuvant Therapy on Tumour Target Expression of Oesophageal Cancer Tissue for NIR Fluorescence Imaging

Author

Galema, Hidde A., Neijenhuis, Lisanne K. A., Lauwerends, Lorraine J., Dekker-Ensink, N. Geeske, Verhoef, Cornelis, Vahrmeijer, Alexander L., Bhairosingh, Shadhvi S., Kuppen, Peter J. K., Rogalla, Stephan, Burggraaf, Jacobus, Lagarde, Sjoerd M., Wijnhoven, Bas P. L., Hutteman, Merlijn, Doukas, Michail, Keereweer, Stijn, and Hilling, Denise E.

Published
2024
Full Text
View/download PDF

2. Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort Study

Author

van der Zijden, Charlène J., van der Sluis, Pieter C., Mostert, Bianca, Nuyttens, Joost J. M. E., van Lanschot, J. Jan B., Spaander, Manon C. W., Valkema, Roelf, Coene, Peter Paul L. O., Dekker, Jan Willem T., Fiets, Willem E., Hartgrink, Hendrik H., Hazen, Wouter L., Kouwenhoven, Ewout A., Nieuwenhuijzen, Grard A. P., Rosman, Camiel, van Sandick, Johanna W., Sosef, Meindert N., van der Zaag, Edwin S., Lagarde, Sjoerd M., and Wijnhoven, Bas P. L.

Published
2024
Full Text
View/download PDF

3. Impact of 18FFDG-PET/CT and Laparoscopy in Staging of Locally Advanced Gastric Cancer: A Cost Analysis in the Prospective Multicenter PLASTIC-Study

Author

de Jongh, Cas, van der Meulen, Miriam P., Gertsen, Emma C., Brenkman, Hylke J. F., van Sandick, Johanna W., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D. P., Nieuwenhuijzen, Grard A. P., van Lanschot, Jan J. B., Lagarde, Sjoerd M., Wijnhoven, Bas P. L., de Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H. M. B., Hulsewe, Karel W. E., Spillenaar Bilgen, Ernst Jan, van Det, Marc J., Kouwenhoven, Ewout A., Daams, Freek, van der Peet, Donald L., van Grieken, Nicole C. T., Heisterkamp, Joos, van Etten, Boudewijn, van den Berg, Jan-Willem, Pierie, Jean-Pierre, Eker, Hasan H., Thijssen, Annemieke Y., Belt, Eric J. T., van Duijvendijk, Peter, Wassenaar, Eelco, Wevers, Kevin P., Hol, Lieke, Wessels, Frank J., Haj Mohammad, Nadia, Frederix, Geert W. J., van Hillegersberg, Richard, Siersema, Peter D., Vegt, Erik, and Ruurda, Jelle P.

Published
2024
Full Text
View/download PDF

9. A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2

Author

van der Zijden, Charlène J., Lagarde, Sjoerd M., Hermus, Merel, Kranenburg, Leonieke W., van Lanschot, J. Jan B., Mostert, Bianca, Nuyttens, Joost J. M. E., Oudijk, Lindsey, van der Sluis, Pieter C., Spaander, Manon C. W., Valkema, Maria J., Valkema, Roelf, and Wijnhoven, Bas P. L.

Published
2023
Full Text
View/download PDF

12. Evolution in Laparoscopic Gastrectomy From a Randomized Controlled Trial Through National Clinical Practice

Author

Markar, Sheraz R., Visser, Maurits R., van der Veen, Arjen, Luyer, Misha D.P., Nieuwenhuijzen, Grard, Stoot, Jan H.M.B., Tegels, Juul J.W., Wijnhoven, Bas P.L., Lagarde, Sjoerd M., de Steur, Wobbe O., Hartgrink, Henk H., Kouwenhoven, Ewout A., Wassenaar, Eelco B., Draaisma, Werner A., Gisbertz, Suzanne S., van Berge Henehouwen, Mark I., van der Peet, Donald L., Ruurda, Jelle P., and van Hillegersberg, Richard

Published
2024
Full Text
View/download PDF

14. ASO Visual Abstract: Gastrointestinal Symptoms After Resection of Esophagogastric Cancer: A Longitudinal Study on Their Incidence and Impact on Patient-Reported Outcomes

Author

van Erning, Felice N., Nieuwenhuijzen, Grard A. P., van Laarhoven, Hanneke W. M., Rosman, Camiel, Gisbertz, Suzanne S., Heisterkamp, Joos, Lagarde, Sjoerd M., Slingerland, Marije, van den Berg, Jan-Willem, Kouwenhoven, Ewout A., Verhoeven, Rob H. A., and Vissers, Pauline A. J.

Published
2023
Full Text
View/download PDF

15. The Comprehensive Complication Index versus Clavien-Dindo grading after laparoscopic and open D2-gastrectomy in the multicenter randomized LOGICA-trial

Author

Brenkman, Hylke J.F., van der Veen, Arjen, Nieuwenhuijzen, Grard A.P., Ponten, Jeroen E.H., Tegels, Juul J.W., Hulsewe, Karel W.E., Wijnhoven, Bas P.L., Lanschot, Jan J.B., de Steur, Wobbe O., Hartgrink, Henk H., Kouwenhoven, Ewout A., van Det, Marc J., Wassenaar, Eelco B., van Duijvendijk, P., Draaisma, Werner A., Broeders, Ivo A.M.J., van der Peet, Donald L., Gisbertz, Suzanne S., Triemstra, Lianne, de Jongh, Cas, Tedone, Fabrizio, Brosens, Lodewijk A.A., Luyer, Misha D.P., Stoot, Jan H.M.B., Lagarde, Sjoerd M., van Hillegersberg, Richard, and Ruurda, Jelle P.

Published
2023
Full Text
View/download PDF

16. Surgical quality and prospective quality control of the D2-gastrectomy for gastric cancer in the multicenter randomized LOGICA-trial

Author

Brenkman, Hylke JF., Seesing, Maarten F.J., Luyer, Misha DP., Ponten, Jeroen EH., Tegels, Juul JW., Hulsewe, Karel WE., Hartgrink, Henk H., Wijnhoven, Bas PL., Lagarde, Sjoerd M., Kouwenhoven, Ewout A., van Det, Marc J., Wassenaar, Eelco B., van Duijvendijk, P., Draaisma, Werner A., Broeders, Ivo AMJ., van der Peet, Donald L., Gisbertz, Suzanne S., de Jongh, Cas, Triemstra, Lianne, van der Veen, Arjen, Brosens, Lodewijk AA., Nieuwenhuijzen, Grard AP., Stoot, Jan HMB., de Steur, Wobbe O., Ruurda, Jelle P., and van Hillegersberg, Richard

Published
2023
Full Text
View/download PDF

18. Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Author

Guchelaar, Niels A. D., Noordman, Bo J., Koolen, Stijn L. W., Mostert, Bianca, Madsen, Eva V. E., Burger, Jacobus W. A., Brandt-Kerkhof, Alexandra R. M., Creemers, Geert-Jan, de Hingh, Ignace H. J. T., Luyer, Misha, Bins, Sander, van Meerten, Esther, Lagarde, Sjoerd M., Verhoef, Cornelis, Wijnhoven, Bas P. L., and Mathijssen, Ron. H. J.

Published
2023
Full Text
View/download PDF

19. A quantitative assessment of perfusion of the gastric conduit after oesophagectomy using near-infrared fluorescence with indocyanine green

Author

de Steur, Wobbe O., Hartgrink, Henk H., Vahrmeijer, Alexander L., Hutteman, Merlijn, Mieog, J. Sven.D., Lagarde, Sjoerd M., van der Sluis, Pieter C., Wijnhoven, Bas P.L., Verhoef, Cornelis, Burggraaf, Jacobus, Keereweer, Stijn, Galema, Hidde A., Faber, Robin A., Tange, Floris P., Hilling, Denise E., and van der Vorst, Joost R.

Published
2023
Full Text
View/download PDF

20. Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study

Author

Elliott, Jessie A., Klevebro, Fredrik, Mantziari, Styliani, Markar, Sheraz R., Goense, Lucas, Johar, Asif, Lagergren, Pernilla, Zaninotto, Giovanni, van Hillegersberg, Richard, van Berge Henegouwen, Mark I., Schäfer, Markus, Nilsson, Magnus, Hanna, George B., Reynolds, John V., Van Veer, Hans, Depypere, Lieven, Coosemans, Willy, Nafteux, Philippe, Carroll, Paul, Allison, Frances, Darling, Gail, Findlay, John M, Everden, Serenydd, Maynard, Nicholas D, Ariyarathenam, Arun, Sanders, Grant, Jaunoo, Shameen, Singh, Pritam, Parsons, Simon, Saunders, John, Vohra, Ravinder, Sinha, Aaditya, Tan, Benjamin HL., Whiting, John G, Boshier, Piers R, Phillips, Alexander W, Griffin, S Michael, Walker, Robert C., Underwood, Tim J, Piessen, Guillaume, Theisen, Jorg, Friess, Hans, Bruns, Christiane J., Schröder, Wolfgang, Collins, Chris G, McAnena, Oliver J, Rooney, Siobhan, Quinn, Aoife, Toale, Conor, Murphy, Thomas J, Ravi, Narayanasamy, Donohoe, Claire L, Scarpa, Marco, Bardini, Romeo, Degasperi, Silvia, Saadeh, Luca, Castoro, Carlo, Alfieri, Rita, Pinto, Eleonora, Mattara, Genny, Kalff, Marianne C, Gisbertz, Suzanne S, Berge Henegouwen, Mark I Van, van Hootegem, Sander JM, Lagarde, Sjoerd M, Lanschot, J Jan B van, Kingma, B Feike, Rurrda, Jelle P, van Hillegersberg, Richard, Kennedy, Raymond, Carey, P. Declan, Prodehl, Leanne, Lamb, Peter J, Skipworth, Richard JE, Cero, Mariagiulia Dal, Pera, Manuel, Huang, Biying, Linder, Gustav, Sundbom, Magnus, Mantziari, Styliani, Schäfer, Markus, and Demartines, Nicolas

Published
2023
Full Text
View/download PDF

22. Influence of postoperative complications following esophagectomy for cancer on quality of life: A European multicenter study

Author

Markar, Sheraz R., Zaninotto, Giovanni, Castoro, Carlo, Johar, Asif, Lagergren, Pernilla, Elliott, Jessie A., Gisbertz, Suzanne S., Mariette, Christophe, Alfieri, Rita, Huddy, Jeremy, Sounderajah, Viknesh, Pinto, Eleonora, Scarpa, Marco, Klevebro, Fredrik, Sunde, Berit, Murphy, Conor F., Greene, Christine, Ravi, Narayanasamy, Piessen, Guillaume, Brenkman, Hylke, Ruurda, Jelle P., Hillegersberg, Richard Van, Lagarde, Sjoerd, Wijnhoven, Bas, Pera, Manuel, Roig, José, Castro, Sandra, Matthijsen, Robert, Findlay, John, Antonowicz, Stefan, Maynard, Nick, McCormack, Orla, Ariyarathenam, Arun, Sanders, Grant, Cheong, Edward, Jaunoo, Shameen, Allum, William, Lanschot, Jan Van, Nilsson, Magnus, Reynolds, John V., van Berge Henegouwen, Mark I., Hanna, George B., Schuring, N., Jezerskyte, E., van Berge Henegouwen, M.I., Sprangers, M.A.G., Lagergren, P., Johar, A., Markar, S.R., and Gisbertz, S.S.

Published
2023
Full Text
View/download PDF

23. Overall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study

Author

van der Zijden, Charlène J, primary, Bouwman, Anna, additional, Mostert, Bianca, additional, Nuyttens, Joost J M E, additional, van der Sluis, Pieter C, additional, Spaander, Manon C W, additional, Mens, Jan Willem M, additional, Homs, Marjolein Y V, additional, van Doorn, Leni, additional, Wijnhoven, Bas P L, additional, and Lagarde, Sjoerd M, additional

Published
2024
Full Text
View/download PDF

24. Body Composition Is a Predictor for Postoperative Complications After Gastrectomy for Gastric Cancer: a Prospective Side Study of the LOGICA Trial

Author

Tweed, Thaís T. T., van der Veen, Arjen, Tummers, Stan, van Dijk, David P. J., Luyer, Misha D. P., Ruurda, Jelle P., van Hillegersberg, Richard, Stoot, Jan H. M. B., Tegels, Juul J. W., Hulsewe, Karel W. E., Brenkman, Hylke J. F., Seesing, Maarten F. J., Nieuwenhuijzen, Grard A. P., Ponten, Jeroen E. H., Wijnhoven, Bas P. L., Lagarde, Sjoerd M., de Steur, Wobbe O., Hartgrink, Henk H., Kouwenhoven, Ewout A., van Det, Marc J., Wassenaar, Eelco B., van der Zaag, Edwin S., Draaisma, Werner A., Broeders, Ivo A. M. J., Gisbertz, Suzanne S., van Berge Henegouwen, Mark I., and van Laarhoven, Hanneke W. M.

Published
2022
Full Text
View/download PDF

27. Overall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study.

Author

Zijden, Charlène J van der, Bouwman, Anna, Mostert, Bianca, Nuyttens, Joost J M E, Sluis, Pieter C van der, Spaander, Manon C W, Mens, Jan Willem M, Homs, Marjolein Y V, Doorn, Leni van, Wijnhoven, Bas P L, and Lagarde, Sjoerd M

Subjects
CANCER relapse, SQUAMOUS cell carcinoma, OVERALL survival, PATIENT preferences, DISEASE relapse, ESOPHAGEAL cancer
Abstract

Definitive chemoradiotherapy (dCRT) is a potentially curative therapy for esophageal cancer. As indications for dCRT differ widely, it is challenging to draw conclusions on outcomes and survival. The aim of this study was to evaluate overall survival (OS) and recurrence patterns according to indications for treatment. Patients who underwent dCRT (50.4 Gy concomitant with carboplatin/paclitaxel) for esophageal cancer between 2012 and 2022 were identified. Indications for dCRT were: cervical tumor, irresectable disease, unfit for surgery, and patient and/or physician preference. The primary endpoint was OS calculated with the Kaplan–Meier method. Secondary endpoints included the proportion of patients that completed the dCRT regimen, 30- and 90-day mortality, and disease recurrence. One hundred and fifty-seven patients were included (72.6% esophageal squamous cell carcinoma) with a median follow-up of 20 months (IQR 10.0–43.9). The full dCRT regimen was completed by 116 patients (73.9%). Thirty- and 90-day mortality were 2.5% and 8.3%, respectively. Median and 5-year OS for all patients were 22.9 months (95% CI 18.0–27.9) and 31.4%, respectively. The median OS per indication was 23.7 months (95% CI 6.5–40.8) for patients with cervical tumors, 10.9 months (95% 0.0–23.2) for irresectable disease, 28.2 months (95% CI 12.3–44.0) for unfit patients, and 22.9 months (95% CI 15.4–30.5) for patients' preference for dCRT (P  = 0.11). Disease recurrence was observed in 74 patients (46%), located locoregionally (46%), distant (19%), or combined (35%). Patients who underwent dCRT had a 5-year OS of 31.4%, but OS differed according to indications for treatment with patients who had irresectable disease having the worst prognosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. An International Multicenter Study Exploring Whether Surveillance After Esophageal Cancer Surgery Impacts Oncological and Quality of Life Outcomes (ENSURE)

Author

Elliott, Jessie A., Markar, Sheraz R., Klevebro, Fredrik, Johar, Asif, Goense, Lucas, Lagergren, Pernilla, Zaninotto, Giovanni, van Hillegersberg, Richard, van Berge Henegouwen, Mark I., Nilsson, Magnus, Hanna, George B., Reynolds, John V., Van Veer, Hans, Depypere, Lieven, Coosemans, Willy, Nafteux, Philippe, Carroll, Paul, Allison, Frances, Darling, Gail, Findlay, John M, Everden, Serenydd, Maynard, Nicholas D, Ariyarathenam, Arun, Sanders, Grant, Jaunoo, Shameen, Singh, Pritam, Parsons, Simon, Saunders, John, Vohra, Ravinder, Sinha, Aaditya, HLTan, Benjamin, Whiting, John G, Boshier, Piers R, Phillips, Alexander W, Griffin, S Michael, Walker, Robert C, Underwood, Tim J, Piessen, Guillaume, Theisen, Jorg, Friess, Hans, Bruns, Christiane J, Schröder, Wolfgang, Collins, Chris G, McAnena, Oliver J, Rooney, Siobhan, Quinn, Aoife, Toale, Conor, Murphy, Thomas J, Ravi, Narayanasamy, Donohoe, Claire L, Scarpa, Marco, Bardini, Romeo, Degasperi, Silvia, Saadeh, Luca, Castoro, Carlo, Alfieri, Rita, Pinto, Eleonora, Mattara, Genny, Kalff, Marianne C, Gisbertz, Suzanne S, Van Berge Henegouwen, Mark I, van Hootegem, Sander JM, Lagarde, Sjoerd M, Wijnhoven, Bas PL, van Lanschot, J Jan B, Kingma, B Feike, Rurrda, Jelle P, van Hillegersberg, Richard, Kennedy, Raymond, Carey, P Declan, Prodehl, Leanne, Lamb, Peter J, Skipworth, Richard JE, Cero, Mariagiulia Dal, Pera, Manuel, Huang, Biying, Linder, Gustav, Sundbom, Magnus, Mantziari, Styliani, Schäfer, Markus, Allemann, Pierre, and Demartines, Nicolas

Published
2023
Full Text
View/download PDF

29. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care: The Dutch Nationwide Ivory Study

Author

Kalff, Marianne C., van Berge Henegouwen, Mark I., Baas, Peter C., Bahadoer, Renu R., Belt, Eric J. T., Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., Drost, Manon, van Duijvendijk, Peter, Eshuis, Wietse J., van Esser, Stijn, Gaspersz, Marcia P., Görgec, Burak, Groenendijk, Richard P. R., Hartgrink, Henk H., van der Harst, Erwin, Haveman, Jan Willem, Heisterkamp, Joos, van Hillegersberg, Richard, Kelder, Wendy, Kingma, B. Feike, Koemans, Willem J., Kouwenhoven, Ewout A., Lagarde, Sjoerd M., Lecot, Frederik, van der Linden, Philip P., Luyer, Misha D. P., Nieuwenhuijzen, Grard A. P., Olthof, Pim B., van der Peet, Donald L., Pierie, Jean-Pierre E. N., Pierik, E. G. J. M. Robert, Plat, Victor D., Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Scheer, Rene, Slootmans, Cettela A. M., Sosef, Meindert N., Sosef, Odin V., de Steur, Wobbe O., Stockmann, Hein B. A. C., Stoop, Fanny J., Voeten, Daan M., Vugts, Guusje, Vijgen, Guy H. E. J., Weeda, Víola B., Wiezer, Marinus J., van Oijen, Martijn G. H., and Gisbertz, Suzanne S.

Published
2023
Full Text
View/download PDF

32. Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT

Author

Geerts, Julie F. M., primary, van der Zijden, Charlène J., additional, van der Sluis, Pieter C., additional, Spaander, Manon C. W., additional, Nieuwenhuijzen, Grard A. P., additional, Rosman, Camiel, additional, van Laarhoven, Hanneke W. M., additional, Verhoeven, Rob H. A., additional, Wijnhoven, Bas P. L., additional, Lagarde, Sjoerd M., additional, and Mostert, Bianca, additional

Published
2024
Full Text
View/download PDF

33. Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study

Author

Bangma, Chris, Beetz, Ivo, Bindels, Patrick, Brandt-Kerkhof, Alexandra, van Diepen, Danielle, Dirven, Clemens, Galema, Tjebbe, Goudzwaard, Jeanette, Hazes, Mieke, Lagarde, Sjoerd, Polinder-Bos, Harmke, Roes, Eva Maria, Takkenberg, Hanneke, van Vledder, Mark, Gravesteijn, Benjamin, Krijkamp, Eline, Busschbach, Jan, Geleijnse, Geert, Helmrich, Isabel Retel, Bruinsma, Sophie, van Lint, Céline, van Veen, Ernest, Steyerberg, Ewout, Verhoef, Kees, van Saase, Jan, Lingsma, Hester, and Baatenburg de Jong, Rob

Published
2021
Full Text
View/download PDF

34. Intraperitoneal chemotherapy for peritoneal metastases of gastric origin:a systematic review and meta-analysis

Author

Guchelaar, Niels A.D., Nasserinejad, Kazem, Mostert, Bianca, Koolen, Stijn L.W., Van Der Sluis, Pieter C., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., Mathijssen, Ron H.J., Noordman, Bo J., Guchelaar, Niels A.D., Nasserinejad, Kazem, Mostert, Bianca, Koolen, Stijn L.W., Van Der Sluis, Pieter C., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., Mathijssen, Ron H.J., and Noordman, Bo J.

Abstract

Background: Gastric cancer with peritoneal metastases is associated with a dismal prognosis. Normothermic catheter-based intraperitoneal chemotherapy and normothermic pressurized intraperitoneal aerosol chemotherapy (PIPAC) are methods to deliver chemotherapy intraperitoneally leading to higher intraperitoneal concentrations of cytotoxic drugs compared to intravenous administration. We reviewed the effectiveness and safety of different methods of palliative intraperitoneal chemotherapy. Methods: Embase, MEDLINE, Web of Science and Cochrane were searched for articles studying the use of repeated administration of palliative intraperitoneal chemotherapy in patients with gastric cancer and peritoneal metastases, published up to January 2024. The primary outcome was overall survival. Results: Twenty-three studies were included, representing a total of 999 patients. The pooled median overall survival was 14.5 months. The pooled hazard ratio of the two RCTs using intraperitoneal paclitaxel and docetaxel favoured the intraperitoneal chemotherapy arm. The median overall survival of intraperitoneal paclitaxel, intraperitoneal docetaxel and PIPAC with cisplatin and doxorubicin were respectively 18.4 months, 13.2 months and 9.0 months. All treatment methods had a relatively safe toxicity profile. Conversion surgery after completion of intraperitoneal therapy was performed in 16% of the patients.Conclusions: Repeated intraperitoneal chemotherapy, regardless of method of administration, is safe for patients with gastric cancer and peritoneal metastases. Conversion surgery after completion of the intraperitoneal chemotherapy is possible in a subset of patients.

Published
2024

35. 18F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapy

Author

Valkema, Maria J., de Lussanet de la Sablonière, Quido G., Valkema, Roelf, Thomeer, Maarten G.J., Dwarkasing, Roy S., Harteveld, Anita A., Doukas, Michail, Mostert, Bianca, van der Zijden, Charlène J., van der Sluis, Pieter C., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., Verburg, Frederik A., van Lanschot, J. Jan B., Valkema, Maria J., de Lussanet de la Sablonière, Quido G., Valkema, Roelf, Thomeer, Maarten G.J., Dwarkasing, Roy S., Harteveld, Anita A., Doukas, Michail, Mostert, Bianca, van der Zijden, Charlène J., van der Sluis, Pieter C., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., Verburg, Frederik A., and van Lanschot, J. Jan B.

Abstract

PURPOSE: The purpose of this study was to investigate whether 18F-fluorodeoxyglucose ( 18 F-FDG) PET/MRI may potentially improve tumor detection after neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer. METHODS: This was a prospective, single-center feasibility study. At 6-12 weeks after nCRT, patients underwent standard 18 F-FDG PET/computed tomography (CT) followed by PET/MRI, and completed a questionnaire to evaluate burden. Two teams of readers either assessed the 18 F-FDG PET/CT or the 18 F-FDG PET/MRI first; the other scan was assessed 1 month later. Maximum standardized uptake value corrected for lean body mass (SUL max ) and mean apparent diffusion coefficient (ADC mean ) were measured at the primary tumor location. Histopathology of the surgical resection specimen served as the reference standard for diagnostic accuracy calculations. When patients had a clinically complete response and continued active surveillance, response evaluations until 9 months after nCRT served as a proxy for ypT and ypN (i.e. 'ycT' and 'ycN'). RESULTS: In the 21 included patients [median age 70 (IQR 62-75), 16 males], disease recurrence was found in the primary tumor in 14 (67%) patients (of whom one ypM+, detected on both scans) and in locoregional lymph nodes in six patients (29%). Accuracy (team 1/team 2) to detect yp/ycT+ with 18 F-FDG PET/MRI vs. 18 F-FDG PET/CT was 38/57% vs. 76/61%. For ypN+, accuracy was 63/53% vs. 63/42%, resp. Neither SUL max (both scans) nor ADC mean were discriminatory for yp/ycT+ . Fourteen of 21 (67%) patients were willing to undergo a similar 18 F-FDG PET/MRI examination in the future. CONCLUSION: 18 F-FDG PET/MRI currently performs comparably to 18 F-FDG PET/CT. Improvements in the scanning protocol, increasing reader experience and performing serial scans might contribute to enhancing the accuracy of tumor detection after nCRT using 18 F-FDG PET/MRI. TRIAL REGISTRATION: Netherlands Trial Register NL9352.

Published
2024

36. Sex-related differences in oncologic outcomes, operative complications and health-related quality of life after curative-intent oesophageal cancer treatment: multicentre retrospective analysis

Author

MS CGO, Cancer, Mantziari, Styliani, Elliott, Jessie A., Markar, Sheraz R., Klevebro, Fredrik, Goense, Lucas, Johar, Asif, Lagergren, Pernilla, Zaninotto, Giovanni, van Hillegersberg, Richard, van Berge Henegouwen, Mark I., Schäfer, Markus, Nilsson, Magnus, Hanna, George B., Reynolds, John V., Van Veer, Hans, Depypere, Lieven, Coosemans, Willy, Nafteux, Philippe, Carroll, Paul, Allison, Frances, Darling, Gail, Findlay, John M., Everden, Serenydd, Maynard, Nicholas D., Ariyarathenam, Arun, Sanders, Grant, Jaunoo, Shameen, Singh, Pritam, Parsons, Simon, Saunders, John, Vohra, Ravinder, Sinha, Aaditya, Tan, Benjamin H.L., Whiting, John G., Boshier, Piers R., Phillips, Alexander W., Griffin, S. Michael, Walker, Robert C., Underwood, Tim J., Piessen, Guillaume, Theisen, Jorg, Friess, Hans, Bruns, Christiane J., Schröder, Wolfgang, Collins, Chris G., McAnena, Oliver J., Rooney, Siobhan, Quinn, Aoife, Toale, Conor, Murphy, Thomas J., Ravi, Narayanasamy, Donohoe, Claire L., Scarpa, Marco, Bardini, Romeo, Degasperi, Silvia, Saadeh, Luca, Castoro, Carlo, Alfieri, Rita, Pinto, Eleonora, Mattara, Genny, Kalff, Marianne C., Gisbertz, Suzanne S., van Hootegem, Sander J.M., Lagarde, Sjoerd M., Kingma, B. Feike, Ruurda, Jelle P., Kennedy, Raymond, Carey, P. Declan, Prodehl, Leanne, Lamb, Peter J., Skipworth, Richard J.E., Dal Cero, Mariagiulia, Pera, Manuel, Huang, Biying, Linder, Gustav, Sundbom, Magnus, Demartines, Nicolas, MS CGO, Cancer, Mantziari, Styliani, Elliott, Jessie A., Markar, Sheraz R., Klevebro, Fredrik, Goense, Lucas, Johar, Asif, Lagergren, Pernilla, Zaninotto, Giovanni, van Hillegersberg, Richard, van Berge Henegouwen, Mark I., Schäfer, Markus, Nilsson, Magnus, Hanna, George B., Reynolds, John V., Van Veer, Hans, Depypere, Lieven, Coosemans, Willy, Nafteux, Philippe, Carroll, Paul, Allison, Frances, Darling, Gail, Findlay, John M., Everden, Serenydd, Maynard, Nicholas D., Ariyarathenam, Arun, Sanders, Grant, Jaunoo, Shameen, Singh, Pritam, Parsons, Simon, Saunders, John, Vohra, Ravinder, Sinha, Aaditya, Tan, Benjamin H.L., Whiting, John G., Boshier, Piers R., Phillips, Alexander W., Griffin, S. Michael, Walker, Robert C., Underwood, Tim J., Piessen, Guillaume, Theisen, Jorg, Friess, Hans, Bruns, Christiane J., Schröder, Wolfgang, Collins, Chris G., McAnena, Oliver J., Rooney, Siobhan, Quinn, Aoife, Toale, Conor, Murphy, Thomas J., Ravi, Narayanasamy, Donohoe, Claire L., Scarpa, Marco, Bardini, Romeo, Degasperi, Silvia, Saadeh, Luca, Castoro, Carlo, Alfieri, Rita, Pinto, Eleonora, Mattara, Genny, Kalff, Marianne C., Gisbertz, Suzanne S., van Hootegem, Sander J.M., Lagarde, Sjoerd M., Kingma, B. Feike, Ruurda, Jelle P., Kennedy, Raymond, Carey, P. Declan, Prodehl, Leanne, Lamb, Peter J., Skipworth, Richard J.E., Dal Cero, Mariagiulia, Pera, Manuel, Huang, Biying, Linder, Gustav, Sundbom, Magnus, and Demartines, Nicolas

Published
2024

37. Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT

Author

Geerts, Julie F.M., Zijden, C.J. van der, Sluis, P.C. van der, Spaander, M.C.W., Nieuwenhuijzen, Grard A. P., Rosman, C., Lagarde, Sjoerd M., Mostert, Bianca, Geerts, Julie F.M., Zijden, C.J. van der, Sluis, P.C. van der, Spaander, M.C.W., Nieuwenhuijzen, Grard A. P., Rosman, C., Lagarde, Sjoerd M., and Mostert, Bianca

Abstract

Contains fulltext : 305683.pdf (Publisher’s version ) (Open Access)

Published
2024

38. Impact of 18FFDG-PET/CT and Laparoscopy in Staging of Locally Advanced Gastric Cancer:A Cost Analysis in the Prospective Multicenter PLASTIC-Study

Author

de Jongh, Cas, Gertsen, Emma C., van der Meulen, Miriam P., Brenkman, Hylke J.F., van Sandick, Johanna W., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., van Lanschot, Jan J.B., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., de Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H.M.B., Hulsewe, Karel W.E., Spillenaar Bilgen, Ernst Jan, van Det, Marc J., Kouwenhoven, Ewout A., Daams, Freek, van der Peet, Donald L., van Grieken, Nicole C.T., Heisterkamp, Joos, van Etten, Boudewijn, van den Berg, Jan Willem, Pierie, Jean Pierre, Eker, Hasan H., Thijssen, Annemieke Y., Belt, Eric J.T., van Duijvendijk, Peter, Wassenaar, Eelco, Wevers, Kevin P., Hol, Lieke, Wessels, Frank J., Haj Mohammad, Nadia, Frederix, Geert W.J., van Hillegersberg, Richard, Siersema, Peter D., Vegt, Erik, Ruurda, Jelle P., de Jongh, Cas, Gertsen, Emma C., van der Meulen, Miriam P., Brenkman, Hylke J.F., van Sandick, Johanna W., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., van Lanschot, Jan J.B., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., de Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H.M.B., Hulsewe, Karel W.E., Spillenaar Bilgen, Ernst Jan, van Det, Marc J., Kouwenhoven, Ewout A., Daams, Freek, van der Peet, Donald L., van Grieken, Nicole C.T., Heisterkamp, Joos, van Etten, Boudewijn, van den Berg, Jan Willem, Pierie, Jean Pierre, Eker, Hasan H., Thijssen, Annemieke Y., Belt, Eric J.T., van Duijvendijk, Peter, Wassenaar, Eelco, Wevers, Kevin P., Hol, Lieke, Wessels, Frank J., Haj Mohammad, Nadia, Frederix, Geert W.J., van Hillegersberg, Richard, Siersema, Peter D., Vegt, Erik, and Ruurda, Jelle P.

Abstract

Background: Unnecessary D2-gastrectomy and associated costs can be prevented after detecting non-curable gastric cancer, but impact of staging on treatment costs is unclear. This study determined the cost impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG-PET/CT) and staging laparoscopy (SL) in gastric cancer staging. Materials and Methods:In this cost analysis, four staging strategies were modeled in a decision tree: (1) 18FFDG-PET/CT first, then SL, (2) SL only, (3) 18FFDG-PET/CT only, and (4) neither SL nor 18FFDG-PET/CT. Costs were assessed on the basis of the prospective PLASTIC-study, which evaluated adding 18FFDG-PET/CT and SL to staging advanced gastric cancer (cT3–4 and/or cN+) in 18 Dutch hospitals. The Dutch Healthcare Authority provided 18FFDG-PET/CT unit costs. SL unit costs were calculated bottom-up. Gastrectomy-associated costs were collected with hospital claim data until 30 days postoperatively. Uncertainty was assessed in a probabilistic sensitivity analysis (1000 iterations). Results: 18FFDG-PET/CT costs were €1104 including biopsy/cytology. Bottom-up calculations totaled €1537 per SL. D2-gastrectomy costs were €19,308. Total costs per patient were €18,137 for strategy 1, €17,079 for strategy 2, and €19,805 for strategy 3. If all patients undergo gastrectomy, total costs were €18,959 per patient (strategy 4). Performing SL only reduced costs by €1880 per patient. Adding 18FFDG-PET/CT to SL increased costs by €1058 per patient; IQR €870–1253 in the sensitivity analysis. Conclusions:For advanced gastric cancer, performing SL resulted in substantial cost savings by reducing unnecessary gastrectomies. In contrast, routine 18FFDG-PET/CT increased costs without substantially reducing unnecessary gastrectomies, and is not recomme

Published
2024

39. Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer:Anthracyclin Triplets versus FLOT

Author

Geerts, Julie F.M., van der Zijden, Charlène J., van der Sluis, Pieter C., Spaander, Manon C.W., Nieuwenhuijzen, Grard A.P., Rosman, Camiel, van Laarhoven, Hanneke W.M., Verhoeven, Rob H.A., Wijnhoven, Bas P.L., Lagarde, Sjoerd M., Mostert, Bianca, Geerts, Julie F.M., van der Zijden, Charlène J., van der Sluis, Pieter C., Spaander, Manon C.W., Nieuwenhuijzen, Grard A.P., Rosman, Camiel, van Laarhoven, Hanneke W.M., Verhoeven, Rob H.A., Wijnhoven, Bas P.L., Lagarde, Sjoerd M., and Mostert, Bianca

Abstract

Background: The FLOT4-AIO trial (2019) showed improved survival with perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) compared to anthracyclin triplets in gastric cancer treatment. It is unclear whether these results extend to real-world scenarios in the Netherlands. This study aimed to compare outcomes of perioperative FLOT to anthracyclin triplets in a real-world Dutch gastric cancer population. Methods:Patients diagnosed with resectable (cT2-4a/cTxN0-3/NxM0) gastric or gastro-esophageal junction carcinoma between 2015–2021 who received neoadjuvant FLOT or anthracyclin triplets were selected from the Netherlands Cancer Registry. The primary outcome was overall survival (OS), analyzed through multivariable Cox regression. Secondary outcomes included pathological complete response (pCR), neoadjuvant chemotherapy cycle completion, surgical resection rates, and adjuvant therapy. Results: Adjusted OS showed no significant survival benefit (HR = 0.88, 95% CI 0.77–1.01, p = 0.07), even though the median OS was numerically improved by 8 months with FLOT compared to anthracyclin triplets (48.1 vs. 39.9 months, p = 0.16). FLOT patients were more likely to undergo diagnostic staging laparoscopies (74.2% vs. 44.1%, p < 0.001), had higher rates of completing neoadjuvant chemotherapy (OR = 1.35, 95% CI 1.09–1.68, p = 0.007), receiving adjuvant therapy (OR = 1.34, 95% CI 1.08–1.66, p = 0.08), and achieving pCR (OR = 1.52, 95% CI 1.05–2.20, p = 0.03). No significant differences were observed in (radical) resection rates. Conclusion(s): Real-world data showed no significant OS improvement for FLOT-treated patients compared to anthracyclin triplets, despite more staging laparoscopies. However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuv

Published
2024

40. Outcomes after Surgical Treatment of Oesophagogastric Cancer with Synchronous Liver Metastases:A Multicentre Retrospective Cohort Study

Author

van Hootegem, Sander J.M., de Pasqual, Carlo A., Giacopuzzi, Simone, Van Daele, Elke, Vanommeslaeghe, Hanne, Moons, Johnny, Nafteux, Philippe, van der Sluis, Pieter C., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., van Hootegem, Sander J.M., de Pasqual, Carlo A., Giacopuzzi, Simone, Van Daele, Elke, Vanommeslaeghe, Hanne, Moons, Johnny, Nafteux, Philippe, van der Sluis, Pieter C., Lagarde, Sjoerd M., and Wijnhoven, Bas P.L.

Abstract

Approximately 10–12% of patients with oesophageal or gastric cancer (OGC) present with oligometastatic disease at diagnosis. It remains unclear if there is a role for radical surgery in these patients. We aimed to assess the outcomes of OGC patients who underwent simultaneous treatment for the primary tumour and synchronous liver metastases. Patients with OGC who underwent surgical treatment between 2008 and 2020 for the primary tumour and up to five synchronous liver metastases aiming for complete tumour removal or ablation (i.e., no residual tumour) were identified from four institutional databases. The primary outcome was overall survival (OS), calculated with the Kaplan–Meier method. Secondary outcomes were disease-free survival and postoperative outcomes. Thirty-one patients were included, with complete follow-up data for 30 patients. Twenty-six patients (84%) received neoadjuvant therapy followed by response evaluation. Median OS was 21 months [IQR 9–36] with 2- and 5-year survival rates of 43% and 30%, respectively. While disease recurred in 80% of patients (20 of 25 patients) after radical resection, patients with a solitary liver metastasis had a median OS of 34 months. The number of liver metastases was a prognostic factor for OS (solitary metastasis aHR 0.330; p-value = 0.025). Thirty-day mortality was zero and complications occurred in 55% of patients. Long-term survival can be achieved in well-selected patients who undergo surgical resection of the primary tumour and local treatment of synchronous liver metastases. In particular, patients with a solitary liver metastasis seem to have a favourable prognosis.

Published
2024

41. Fractures and other chest wall abnormalities after thoracotomy for esophageal cancer:A retrospective cohort study

Author

Van Wijck, Suzanne F. M., Barza, Athina, Vermeulen, Jefrey, Eyck, Ben M., van der Wilk, Berend J., van der Harst, Erwin, Verhofstad, Michael H. J., Lagarde, Sjoerd M., Van Lieshout, Esther M. M., Wijffels, Mathieu M. E., Van Wijck, Suzanne F. M., Barza, Athina, Vermeulen, Jefrey, Eyck, Ben M., van der Wilk, Berend J., van der Harst, Erwin, Verhofstad, Michael H. J., Lagarde, Sjoerd M., Van Lieshout, Esther M. M., and Wijffels, Mathieu M. E.

Abstract

Background Chest pain following a thoracotomy for esophageal cancer is frequently reported but poorly understood. This study aimed to (1) determine the prevalence of thoracotomy-related thoracic fractures on postoperative imaging and (2) compare complications, long-term pain, and quality of life in patients with versus without these fractures. Methods This retrospective cohort study enrolled patients with esophageal cancer who underwent a thoracotomy between 2010 and 2020 with pre- and postoperative CTs (<1 and/or >6 months). Disease-free patients were invited for questionnaires on pain and quality of life. Results Of a total of 366 patients, thoracotomy-related rib fractures were seen in 144 (39%) and thoracic transverse process fractures in 4 (2%) patients. Patients with thoracic fractures more often developed complications (89% vs. 74%, p = 0.002), especially pneumonia (51% vs. 39%, p = 0.032). Questionnaires were completed by 77 after a median of 41 (P-25-P(75 )28-91) months. Long-term pain was frequently (63%) reported but was not associated with thoracic fractures (p = 0.637), and neither were quality of life scores. Conclusions Thoracic fractures are prevalent in patients following a thoracotomy for esophageal cancer. These thoracic fractures were associated with an increased risk of postoperative complications, especially pneumonia, but an association with long-term pain or reduced quality of life was not confirmed.

Published
2024

42. Intraoperative Music to Promote Patient Outcome (IMPROMPTU):A Double-Blind Randomized Controlled Trial

Author

Fu, Victor X., Lagarde, Sjoerd M., Favoccia, Christian T., Heisterkamp, Joos, van Oers, Annemarie E., Coene, Peter Paul L.O., Koopman, Josèph S.H.A., van den Berg, Sjoerd A.A., Dik, Willem A., Jeekel, Johannes, Wijnhoven, Bas P.L., Fu, Victor X., Lagarde, Sjoerd M., Favoccia, Christian T., Heisterkamp, Joos, van Oers, Annemarie E., Coene, Peter Paul L.O., Koopman, Josèph S.H.A., van den Berg, Sjoerd A.A., Dik, Willem A., Jeekel, Johannes, and Wijnhoven, Bas P.L.

Abstract

Introduction: Perioperative music can have beneficial effects on postoperative pain, anxiety, opioid requirement, and the physiological stress response to surgery. The aim was to assess the effects of intraoperative music during general anesthesia in patients undergoing surgery for esophagogastric cancer. Materials and methods: The IMPROMPTU study was a double-blind, placebo-controlled, randomized multicenter trial. Adult patients undergoing surgery for stage II-III esophagogastric cancer were eligible. Exclusion criteria were a hearing impairment, insufficient Dutch language knowledge, corticosteroids use, or objection to hearing unknown music. Patients wore active noise-cancelling headphones intraoperatively with preselected instrumental classical music (intervention) or no music (control). Computerized randomization with centralized allocation, stratified according to surgical procedure using variable block sizes, was employed. Primary endpoint was postoperative pain on the first postoperative day. Secondary endpoints were postoperative pain during the first postoperative week, postoperative opioid requirement, intraoperative medication requirement, the stress response to surgery, postoperative complication rate, length of stay, and mortality, with follow-up lasting 30 d. Results: From November 2018 to September 2020, 145 patients were assessed and 83 randomized. Seventy patients (music n = 31, control n = 39) were analyzed. Median age was 70 [IQR 63–70], and 48 patients (69%) were male. Music did not reduce postoperative pain (numeric rating scale 1.8 (SD0.94) versus 2.0 (1.0), mean difference −0.28 [95% CI -0.76–0.19], P = 0.236). No statistically significant differences were seen in medication requirement, stress response, complication rate, or length of stay. Conclusions: Intraoperative, preselected, classical music during esophagogastric cancer surgery did not significantly improve postoperative outcome and recovery when compared to no music using noise-c

Published
2024

43. Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma

Author

Henckens, Sofie P.G., Liu, Dajia, Gisbertz, Suzanne S., Kalff, Marianne C., Anderegg, Maarten C.J., Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., van Duijvendijk, Peter, Eshuis, Wietse J., Groenendijk, Richard P.R., Haveman, Jan Willem, van Hillegersberg, Richard, Luyer, Misha D.P., Olthof, Pim B., Pierie, Jean Pierre E.N., Plat, Victor D., Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Sosef, Meindert N., Voeten, Daan M., Vijgen, Guy H.E.J., Bijlsma, Maarten F., Meijer, Sybren L., Hulshof, Maarten C.C.M., Oyarce, Cesar, Lagarde, Sjoerd M., van Laarhoven, Hanneke W.M., van Berge Henegouwen, Mark I., Henckens, Sofie P.G., Liu, Dajia, Gisbertz, Suzanne S., Kalff, Marianne C., Anderegg, Maarten C.J., Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., van Duijvendijk, Peter, Eshuis, Wietse J., Groenendijk, Richard P.R., Haveman, Jan Willem, van Hillegersberg, Richard, Luyer, Misha D.P., Olthof, Pim B., Pierie, Jean Pierre E.N., Plat, Victor D., Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Sosef, Meindert N., Voeten, Daan M., Vijgen, Guy H.E.J., Bijlsma, Maarten F., Meijer, Sybren L., Hulshof, Maarten C.C.M., Oyarce, Cesar, Lagarde, Sjoerd M., van Laarhoven, Hanneke W.M., and van Berge Henegouwen, Mark I.

Abstract

BACKGROUND: This study evaluated the association of pathological tumour response (tumour regression grade, TRG) and a novel scoring system, combining both TRG and nodal status (TRG-ypN score; TRG1-ypN0, TRG>1-ypN0, TRG1-ypN+ and TRG>1-ypN+), with recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. METHODS: This Dutch nationwide cohort study included patients treated with neoadjuvant chemoradiotherapy followed by oesophagectomy for distal oesophageal or gastro-oesophageal junctional adenocarcinoma between 2007 and 2016. The primary endpoint was the association of Mandard score and TRG-ypN score with recurrence patterns (rate, location, and time to recurrence). The secondary endpoint was overall survival. RESULTS: Among 2746 inclusions, recurrence rates increased with higher Mandard scores (TRG1 30.6%, TRG2 44.9%, TRG3 52.9%, TRG4 61.4%, TRG5 58.2%; P < 0.001). Among patients with recurrent disease, the distribution (locoregional versus distant) was the same for the different TRG groups. Patients with TRG1 developed more brain recurrences (17.7 versus 9.8%; P = 0.001) and had a longer mean overall survival (44 versus 35 months; P < 0.001) than those with TRG>1. The TRG>1-ypN+ group had the highest recurrence rate (64.9%) and worst overall survival (mean 27 months). Compared with the TRG>1-ypN0 group, patients with TRG1-ypN+ had a higher risk of recurrence (51.9 versus 39.6%; P < 0.001) and worse mean overall survival (33 versus 41 months; P < 0.001). CONCLUSION: Improved tumour response to neoadjuvant therapy was associated with lower recurrence rates and higher overall survival rates. Among patients with recurrent disease, TRG1 was associated with a higher incidence of brain recurrence than TRG>1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site.

Published
2024

44. Recurrent Disease After Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study

Author

Kalff, Marianne C., Henckens, Sofie P.G., Voeten, Daan M., Heineman, David J., Hulshof, Maarten C.C.M., van Laarhoven, Hanneke W.M., Eshuis, Wietse J., Baas, Peter C., Bahadoer, Renu R., Belt, Eric J.T., Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., Drost, Manon, van Duijvendijk, Peter, van Esser, Stijn, Gaspersz, Marcia P., Görgec, Burak, Groenendijk, Richard P.R., Hartgrink, Henk H., van der Harst, Erwin, Haveman, Jan W., Heisterkamp, Joos, van Hillegersberg, Richard, Kelder, Wendy, Kingma, B. Feike, Koemans, Willem J., Kouwenhoven, Ewout A., Lagarde, Sjoerd M., Lecot, Frederik, van der Linden, Philip P., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., Olthof, Pim B., van der Peet, Donald L., Pierie, Jean-Pierre E.N., Pierik, E.G.J.M. Robert, Plat, Victor D., Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Scheer, Rene, Slootmans, Cettela A.M., Sosef, Meindert N., Sosef, Odin V., de Steur, Wobbe O., Stockmann, Hein B.A.C., Stoop, Fanny J., Vugts, Guusje, Vijgen, Guy H.E.J., Weeda, Víola B., Wiezer, Marinus J., van Oijen, Martijn G.H., van Berge Henegouwen, Mark I., and Gisbertz, Suzanne S.

Published
2022
Full Text
View/download PDF

45. International Expert Consensus on Semantics of Multimodal Esophageal Cancer Treatment: Delphi Study.

Author

van der Zijden, Charlène J., Lagarde, Sjoerd M., Mostert, Bianca, Nuyttens, Joost J. M. E., Spaander, Manon C. W., Wijnhoven, Bas P. L., van Sandick, Johanna W., van Dieren, Jolanda M., Voncken, Francine E. M., Pierie, Jean-Pierre E. N., Fiets, Willem E., Rosman, Camiel, Siersema, Peter D., Rütten, Heidi, Nieuwenhuijzen, Grard A. P., Creemers, Geert-Jan, Schoon, Erik J., van der Sangen, Maurice J. C., Verschoor, Arjan, and Quispel, Rutger

Abstract

Background: Recent developments in esophageal cancer treatment, including studies exploring active surveillance following chemoradiotherapy, have led to a need for clear terminology and definitions regarding different multimodal treatment options. Objective: The aim of this study was to reach worldwide consensus on the definitions and semantics of multimodal esophageal cancer treatment. Methods: In total, 72 experts working in the field of multimodal esophageal cancer treatment were invited to participate in this Delphi study. The study comprised three Delphi surveys sent out by email and one online meeting. Input for the Delphi survey consisted of terminology obtained from a systematic literature search. Participants were asked to respond to open questions and to indicate whether they agreed or disagreed with different statements. Consensus was reached when there was ≥75% agreement among respondents. Results: Forty-nine of 72 invited experts (68.1%) participated in the first online Delphi survey, 45 (62.5%) in the second survey, 21 (46.7%) of 45 in the online meeting, and 39 (86.7%) of 45 in the final survey. Consensus on neoadjuvant and definitive chemoradiotherapy with or without surgery was reached for 27 of 31 items (87%). No consensus was reached on follow-up after treatment with definitive chemoradiotherapy. Conclusion(s): Consensus was reached on most statements regarding terminology and definitions of multimodal esophageal cancer treatment. Implementing uniform criteria facilitates comparison of studies and promotes international research collaborations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Impact of 18FFDG-PET/CT and Laparoscopy in Staging of Locally Advanced Gastric Cancer: A Cost Analysis in the Prospective Multicenter PLASTIC-Study.

Author

de Jongh, Cas, van der Meulen, Miriam P., Gertsen, Emma C., Brenkman, Hylke J. F., van Sandick, Johanna W., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D. P., Nieuwenhuijzen, Grard A. P., van Lanschot, Jan J. B., Lagarde, Sjoerd M., Wijnhoven, Bas P. L., de Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H. M. B., Hulsewe, Karel W. E., Spillenaar Bilgen, Ernst Jan, van Det, Marc J., Kouwenhoven, Ewout A., and Daams, Freek

Abstract

Background: Unnecessary D2-gastrectomy and associated costs can be prevented after detecting non-curable gastric cancer, but impact of staging on treatment costs is unclear. This study determined the cost impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG-PET/CT) and staging laparoscopy (SL) in gastric cancer staging. Materials and Methods: In this cost analysis, four staging strategies were modeled in a decision tree: (1) 18FFDG-PET/CT first, then SL, (2) SL only, (3) 18FFDG-PET/CT only, and (4) neither SL nor 18FFDG-PET/CT. Costs were assessed on the basis of the prospective PLASTIC-study, which evaluated adding 18FFDG-PET/CT and SL to staging advanced gastric cancer (cT3–4 and/or cN+) in 18 Dutch hospitals. The Dutch Healthcare Authority provided 18FFDG-PET/CT unit costs. SL unit costs were calculated bottom-up. Gastrectomy-associated costs were collected with hospital claim data until 30 days postoperatively. Uncertainty was assessed in a probabilistic sensitivity analysis (1000 iterations). Results: 18FFDG-PET/CT costs were €1104 including biopsy/cytology. Bottom-up calculations totaled €1537 per SL. D2-gastrectomy costs were €19,308. Total costs per patient were €18,137 for strategy 1, €17,079 for strategy 2, and €19,805 for strategy 3. If all patients undergo gastrectomy, total costs were €18,959 per patient (strategy 4). Performing SL only reduced costs by €1880 per patient. Adding 18FFDG-PET/CT to SL increased costs by €1058 per patient; IQR €870–1253 in the sensitivity analysis. Conclusions: For advanced gastric cancer, performing SL resulted in substantial cost savings by reducing unnecessary gastrectomies. In contrast, routine 18FFDG-PET/CT increased costs without substantially reducing unnecessary gastrectomies, and is not recommended due to limited impact with major costs. Trial registration: NCT03208621. This trial was registered prospectively on 30-06-2017. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Outcomes after Surgical Treatment of Oesophagogastric Cancer with Synchronous Liver Metastases: A Multicentre Retrospective Cohort Study

Author

van Hootegem, Sander J. M., primary, de Pasqual, Carlo A., additional, Giacopuzzi, Simone, additional, Van Daele, Elke, additional, Vanommeslaeghe, Hanne, additional, Moons, Johnny, additional, Nafteux, Philippe, additional, van der Sluis, Pieter C., additional, Lagarde, Sjoerd M., additional, and Wijnhoven, Bas P. L., additional

Published
2024
Full Text
View/download PDF

49. Fractures and other chest wall abnormalities after thoracotomy for esophageal cancer: A retrospective cohort study

Author

Van Wijck, Suzanne F. M., primary, Barza, Athiná, additional, Vermeulen, Jefrey, additional, Eyck, Ben M., additional, Van der Wilk, Berend J., additional, Van der Harst, Erwin, additional, Verhofstad, Michael H. J., additional, Lagarde, Sjoerd M., additional, Van Lieshout, Esther M. M., additional, and Wijffels, Mathieu M. E., additional

Published
2024
Full Text
View/download PDF

50. Chemotherapy and chemoradiotherapy for adenocarcinoma of the esophagus and junction with oligometastases: Results of the TNT-OES-1 trial.

Author

van der Zijden, Charlène J., primary, Huizer, Tamara J., additional, Eyck, Ben M., additional, van der Gaast, Ate, additional, Van Doorn, Leni, additional, Homs, Marjolein Y.V., additional, van Lanschot, Jan J.B., additional, Nuyttens, Joost J.M.E., additional, Oudijk, Lindsey, additional, Spaander, Manon C.W., additional, Wijnhoven, Bas P.L., additional, Mostert, Bianca, additional, and Lagarde, Sjoerd M., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results